CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1187953 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.0%
TTM net income YoY-25.4%
TTM EPS YoY29.9%
Revenue 3-yr CAGR-50.4%
Net income 3-yr CAGR—
Margins
Gross margin66.9%
Operating margin-256,435.0%
Net margin-249,160.1%
FCF margin—
EBITDA margin—
Returns
ROE-119.2%
ROA-113.8%
ROIC (approx.)-3,736.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets4.0%
Debt / equity0.00x
Current ratio23.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-16.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $3,000 | $0 | $0 | $3,000 | $3,000 |
| Cost of revenue | $0 | $0 | $0 | $994 | $0 | $0 | $1,200 | $1,200 |
| Gross profit | $0 | $0 | $0 | $2,006 | $0 | $0 | $1,800 | $1,800 |
| R&D expense | $1.60M | $459,200 | $541,658 | $550,077 | $465,154 | $501,261 | $743,304 | $471,840 |
| SG&A expense | $1.11M | $1.08M | $888,640 | $1.37M | $776,821 | $731,517 | $888,397 | $1.39M |
| Operating income | -$2.73M | -$1.56M | -$1.46M | -$1.95M | -$1.27M | -$1.26M | -$1.66M | -$1.89M |
| Pretax income | -$2.66M | -$1.51M | -$1.40M | -$1.89M | -$1.24M | -$1.23M | -$1.64M | -$1.85M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$2.67M | -$1.51M | -$1.41M | -$1.89M | -$1.24M | -$1.23M | -$1.64M | -$1.85M |
| EBITDA | — | — | — | — | — | — | -$1.61M | -$1.88M |
| EPS (diluted) | -0.40 | -0.41 | -0.38 | — | -0.48 | -0.48 | -0.83 | — |
| Weighted avg. shares (diluted) | 6.66M | 3.70M | 3.70M | — | 2.58M | 2.58M | 1.98M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.85M | $8.71M | $5.72M | $7.21M | $5.38M | $6.55M | $7.70M | $5.94M |
| Inventory | — | $125,000 | $125,000 | $0 | $994 | $994 | $994 | $2,194 |
| Current assets | $6.94M | $9.02M | $6.06M | $7.40M | $5.41M | $6.63M | $7.84M | $6.14M |
| Intangibles | $338,806 | $355,459 | $378,377 | $407,230 | $438,181 | $469,240 | $499,982 | $530,559 |
| Total assets | $7.28M | $9.38M | $6.44M | $7.81M | $5.85M | $7.11M | $8.35M | $6.67M |
| Current liabilities | $293,226 | $698,595 | $307,649 | $284,880 | $261,353 | $277,644 | $286,387 | $327,644 |
| Total liabilities | $293,226 | $698,595 | $307,649 | $284,880 | $261,353 | $277,644 | $286,387 | $327,644 |
| Shareholders' equity | $6.95M | $8.65M | $6.11M | $7.51M | $5.59M | $6.83M | $8.06M | $6.34M |
| Shares outstanding | 7.60M | 6.49M | 3.70M | 3.70M | 2.58M | 2.58M | 2.58M | 1.75M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.66M | -$1.47M | -$1.32M | -$1.94M | -$1.17M | -$1.16M | -$1.59M | -$1.95M |
| Investing cash flow | $203,140 | $0 | -$175,000 | -$50,500 | $0 | $0 | $0 | $0 |
| Financing cash flow | -$407,164 | $4.46M | $13,360 | $3.82M | $0 | $0 | $3.35M | $1.63M |
| Depreciation & amortization | — | — | — | — | — | — | $46,000 | $10,000 |
| Stock-based compensation | $970,000 | $0 | $0 | $0 | $0 | $0 | $3,485 | $9,162 |
| Share buybacks | $0 | $0 | $0 | $0 | $0 | $0 | $10,000 | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.